Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Th...( in the Earle A. Chiles Research Institu...)

Date:3/19/2009

, in the Earle A. Chiles Research Institute of Providence Cancer Center, Portland, Oregon. He holds a Ph.D. degree from Wayne State University, Detroit, and did postdoctoral training at the Surgery Branch, Division of Cancer Treatment, of the National Cancer Institute (NCI), NIH. He has appointments as Associate Professor of Molecular Microbiology and Immunology at the School of Medicine of the Oregon Health and Science University (OHSU), and Leader, Tumor Immunology Focus Panel, OHSU Knight Cancer Institute. Prof. Fox participated as principal and co-investigator in numerous clinical trials exploring novel immunotherapeutic approaches. He has particular expertise in the role T cells play in cancer therapy.

"We are very pleased with the addition of two internationally recognized scientists with long-standing expertise in cancer immunotherapy to our advisory panel," commented Christian Itin, president and CEO of Micromet. "Sir Walter Bodmer and Bernard Fox have unique experience in key areas relevant for the development of new BiTE antibodies for the treatment of cancer."

About Micromet

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for
'/>"/>

SOURCE Micromet, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results